Literature DB >> 6684328

Carbocyclic arabinofuranosyladenine (cyclaradine): efficacy against genital herpes in guinea pigs.

R Vince, S Daluge, H Lee, W M Shannon, G Arnett, T W Schafer, T L Nagabhushan, P Reichert, H Tsai.   

Abstract

Carbocyclic arabinofuranosyladenine (cyclaradine), a novel nucleoside analog with such desired features as hydrolytic and enzymatic stability, adenosine deaminase resistance, and low systemic toxicity, inhibited the replication of herpes simplex virus types 1 and 2. The 5'-methoxyacetate prodrug form exhibited significant efficacy in the topical treatment of genital infections by herpes simplex virus type 2.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6684328     DOI： 10.1126/science.6684328

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  5 in total

1.  Antiviral activity of 5-ethyl-2'-deoxyuridine against herpes simplex viruses in cell culture, mice, and guinea pigs.

Authors:  R F Schinazi; R T Scott; J Peters; V Rice; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Activity of (+)-cyclaradine (Sch 31172) against herpes simplex virus in vitro and in vivo.

Authors:  J Schwartz; M Ostrander; N J Butkiewicz; M Lieberman; C Lin; J Lim; G H Miller
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

Review 3.  Antiherpes drugs: promises and pitfalls.

Authors:  E de Clercq
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

4.  Evaluation of (+)-cyclaradine-5'-esters as prodrugs for (+)-cyclaradine in animals.

Authors:  J Lim; J Schwartz; D Loebenberg; G H Miller; S Symchowicz; C Lin
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

5.  Meeting report: 29th International Conference on Antiviral Research in La Jolla, CA, USA.

Authors:  R Anthony Vere Hodge
Journal:  Antiviral Res       Date:  2016-11-01       Impact factor: 5.970
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.